0000000001269736

AUTHOR

F. De Leonardis

showing 6 related works from this author

Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study.

2017

Objective Malignant ovarian germ cell tumors (MOGCT) carry an excellent prognosis, and the treatment aims to achieve results with the least possible treatment-related morbidity. The aim of this study was to assess the outcomes of pediatric patients with MOGCT. Methods Patients were treated according to their stage: surgery and surveillance for stage I; a modified bleomycin–etoposide–cisplatin (BEP) regimen for stages II (three cycles), III, and IV (three cycles) with surgery on residual disease. Results Seventy-seven patients were enrolled (median age 11.8 years), 26 with dysgerminoma (Dysg), 13 with immature teratoma and elevated serum alpha-fetoprotein levels (IT + AFP), and 38 with nondy…

0301 basic medicineMalechildhood; germ cell tumors; ovarianGastroenterology0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesStage (cooking)germ cell tumorsProspective cohort studyChildEtoposideOvarian NeoplasmsHematologychildhood germ cell tumors ovarianNeoplasms Germ Cell and EmbryonalPrognosisCombined Modality TherapySurvival RateOncology030220 oncology & carcinogenesisChild PreschoolFemalemedicine.medical_specialtyAdolescentOvariectomy03 medical and health sciencesBleomycinInternal medicineDysgerminomaovarianHumansSurvival ratechildhoodNeoplasm Stagingbusiness.industrySettore MED/20 - Chirurgia Pediatrica E InfantileInfantmedicine.diseaseSurgeryRegimen030104 developmental biologyPediatrics Perinatology and Child HealthSettore MED/20Immature teratomaGerm cell tumorsCisplatinbusinessProgressive diseaseFollow-Up StudiesPediatric bloodcancer
researchProduct

Odderon Exchange from Elastic Scattering Differences between pp and pp¯ Data at 1.96 TeV and from pp Forward Scattering Measurements

2021

We describe an analysis comparing the p p ¯ elastic cross section as measured by the D0 Collaboration at a center-of-mass energy of 1.96 TeV to that in p p collisions as measured by the TOTEM Collaboration at 2.76, 7, 8, and 13 TeV using a model-independent approach. The TOTEM cross sections, extrapolated to a center-of-mass energy of s = 1.96 TeV , are compared with the D0 measurement in the region of the diffractive minimum and the second maximum of the p p cross section. The two data sets disagree at the 3.4 σ level and thus provide evidence for the t -channel exchange of a colorless, C -odd gluonic compound, also known as the odderon. We combine these results with a TOTEM analysis of th…

Quantum chromodynamicsPhysicsElastic scatteringParticle physics010308 nuclear & particles physicsForward scatterScatteringStrong interactionGeneral Physics and Astronomy01 natural sciencesScattering amplitudeCross section (physics)0103 physical sciences010306 general physicsBar (unit)Physical Review Letters
researchProduct

Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study

2015

s / Digestive and Liver Disease 47S (2015) e1–e18 e7 (months; 95% CI): CPT 0 62 (52.9–71.1), A 44 (41.6–46.4), B 22 (19.7–24.3), C 9 (6.6–11.3), p<0.0001. Comparisons between survivals of CTP 0 vs A, B and C were also statistically different (p<0.0001 in all associations). The prognosis of patients in the intermediateBCLCstagealsodifferedaccording to the liver function (0 vs A vs B, p<0.0001). Conclusions: The newly proposed CTP class 0 identifies a different subgroup of patientswith a better prognosis, alsowhen applied in a European cohort, where HCV aetiology is predominant. This new approach impacts not only on outcome prediction but also, potentially, on treatment allocation, better str…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryGastroenterologymedicine.diseaseInterim analysisGastroenterologyLiver diseaseInternal medicineCohortAscitesmedicineEtiologyLiver functionStage (cooking)medicine.symptombusinessDigestive and Liver Disease
researchProduct

Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S01688278173…

2018

It has come to our attention that the PITER framework investigator, Alessandro Federico, was incorrectly listed as F. Alessandro in the original manuscript. Please note that the correct name of this author is Alessandro Federico (2nd University of Naples). The correct list of PITER investigators is in the footnote below.

HepatologyHepatitis B; EASL guidelines; Treatment; Interferon; Entecavir; Tenofovir; TAF; HBsAg; Hepatocellular carcinoma; HBV DNA; HBV reactivation; Mother to child transmissionHepatocellular carcinomaHBV reactivationEASL guidelinesHepatitis BEntecavirTreatmentHBsAgTAFHBV DNAMother to child transmissionInterferonTenofovirEASL guideline
researchProduct

Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

2017

Background &amp; Aims Premenopausal women who are HCV positive (HCV+) have failing ovarian function, which is likely to impact their fertility. Thus, we investigated the reproductive history, risk of infertility, and pregnancy outcomes in women of childbearing age who were HCV+. Methods Three different groups were studied: (1) Clinical cohort: 100 women who were HCV+ and also had chronic liver disease (CLD), age matched with 50 women who were HBV+ with CLD and with 100 healthy women; all women were consecutively observed in three gastroenterology units in hospitals in Italy; (2) 1,998 women who were HCV+ and enrolled in the Italian Platform for the Study of Viral Hepatitis Therapies (PITER)…

Anti-Mullerian hormone; Antiviral therapy; HBV; HCV; Sustained viral response; HepatologyInfertilitymedicine.medical_specialtySustained viral responsemedia_common.quotation_subjectFertilityAnti-Müllerian hormoneAntiviral therapyMiscarriage03 medical and health sciences0302 clinical medicineHBVMedicineProspective cohort studymedia_commonGynecologyAnti-Müllerian hormone Antiviral therapy HBV HCV Sustained viral response030219 obstetrics & reproductive medicineHepatologybusiness.industryObstetricsAnti-Müllerian hormone; Antiviral therapy; HBV; HCV; Sustained viral responseAnti-Mullerian hormonemedicine.diseaseAnti-Müllerian hormoneGestational diabetesCohortHCV030211 gastroenterology & hepatologyAnti-Müllerian hormone; Antiviral therapy; HBV; HCV; Sustained viral response; HepatologybusinessLive birthCell aging
researchProduct

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

2017

Background & Aims: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. Methods: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N= 200) and w…

Male0301 basic medicinehepatitis C virusSustained Virologic ResponseSofosbuvirHepacivirusDrug ResistanceHepacivirusresistance-associated substitutionsViral Nonstructural ProteinsVARIANTSNS5Amedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRecurrenceINFECTIONantiviral therapyMedicinehepatitis C viruViralTreatment FailureChronicantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; hepatologybiologyGENOTYPE 1virus diseasesMiddle Agedantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutionsSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCombinationInterferonDrug Therapy CombinationFemale030211 gastroenterology & hepatologyAuthor Keywords:antiviral therapyRIBAVIRINSequence AnalysisHumanmedicine.drugmedicine.medical_specialtyDaclatasvirGenotypeHepatitis C virusAntiviral AgentsLONG-TERM PERSISTENCEDACLATASVIR03 medical and health sciencesDrug Therapyantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; Aged; Antiviral Agents; Drug Resistance Viral; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Italy; Male; Middle Aged; Mutation; Recurrence; Ribavirin; Sequence Analysis DNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; HepatologyTREATMENT-NAIVEInternal medicineDrug Resistance ViralRibavirinHumansNS5Aresistance testdirect-acting antiviralsAgedAntiviral Agentresistance-associated substitutiondirect-acting antiviralHepaciviruHepatologyresistance test KeyWords Plus:HEPATITIS-C VIRUSbusiness.industryRibavirinViral Nonstructural ProteinSequence Analysis DNADNAHepatitis C ChronicHepatologybiology.organism_classificationClinical trial030104 developmental biologySOFOSBUVIRchemistrySequence AnalysihepatologyMutationImmunologyInterferonsSofosbuvirbusiness
researchProduct